Praxis Precision Medicines (PRAX)
(Delayed Data from NSDQ)
$50.80 USD
-2.12 (-4.01%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $50.64 -0.16 (-0.31%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
PRAX 50.80 -2.12(-4.01%)
Will PRAX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRAX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PRAX
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
PRAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
Other News for PRAX
Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
What 6 Analyst Ratings Have To Say About Praxis Precision Medicine
PayPal, Kellanova upgraded: Wall Street's top analyst calls
Praxis Precision initiated with bullish view at Oppenheimer, here's why
Are We Having Fun Yet? Stocks Sell Off On Massive Volume